GCP
PACB icon

Gill Capital Partners’s Pacific Biosciences PACB Stock Holding History

Gill Capital Partners’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.34K Sell
800
-177
-18% -$257 ﹤0.01% 600
2026
Q1 		$1.29K Buy
+977
New +$1.75K ﹤0.01% 584

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Gill Capital Partners's PACB Position: Q2 2026 in Review

Gill Capital Partners reduced its Pacific Biosciences (PACB) stake by 18% in Q2 2026, selling an estimated $257 and leaving 800 shares worth $1.34K. The position accounts for ﹤0.01% of the portfolio, ranked #600.

Gill Capital Partners first reported a position in PACB in Q1 2026 and has held it in 2 quarters since. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Gill Capital Partners held 800 shares of Pacific Biosciences worth $1.34K as of Q2 2026.
  • Gill Capital Partners sold 177 Pacific Biosciences shares in Q2 2026, an estimated $257.
  • Pacific Biosciences made up ﹤0.01% of Gill Capital Partners's portfolio in Q2 2026, its #600 holding.
  • Gill Capital Partners first reported a position in Pacific Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Gill Capital Partners's 13F filing for Q2 2026, filed 20 Aug 2026.